The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA).On Dec. 20, ...

The approval supports evidence that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease risk. Other studies are ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand the ...

The Food and Drug Administration has approved ... Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss ...

The move comes as weight-loss ... when the FDA approved Wegovy for cardiovascular disease risk reduction early in 2024,” Juliette Cubanski, a deputy director of KFF, a nonpartisan health-care ...

The U.S. Food and Drug Administration (FDA ... improving overall health. The approval of Zepbound underscores the evolving landscape of OSA management, combining weight-loss benefits with improved ...

The Food and Drug Administration (FDA) approved a weight ... OSA and aids in long-term weight loss in adults with obesity,” the president of Lilly Cardiometabolic Health and Lilly USA Patrik ...

If untreated, obstructive sleep apnea raises the risk for a range of health issues ... Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep ...